Indolent B-Cell Non-Hodgkin Lymphoma — Trials

Indolent B-Cell Non-Hodgkin Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

617 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 172
Recruiting: 85
Ph III recruiting: 4
Growth YoY: +34.6%
Industry share: 22%
Top sponsor: City of Hope Medical Center
Termination share: 34.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (109)

clinicaltrialsPublishedShowing 101–112 of 112 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06700798	Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial	recruiting	Phase 2	90	Fei LiOTHER	1	Jun 17, 2025	clinicaltrials
NCT07022223	Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma	recruiting	Phase 2	51	Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER	1	Jun 15, 2025	clinicaltrials